OUR NEW PROFILE IS: GPOX
-
GPOX is fully reporting OTCQB with just 29.3 million shares outstanding and sitting at 52 week lows at bottom of its range.
-
GPOX’s AntiGenTests.com currently has 3 different covid rapid test kits on sale: CareStart™ COVID-19 Antigen Test, Flowflex™ COVID-19 Antigen Test, and iHealth® COVID-19 Antigen Test
-
Due to the COVID test supply shortages, one of GPOX main value propositions has been getting tests delivered the next day! As a result GPOX revenues have ramped up in recent months
-
GPOX revenues have ramped up over the past few months with the Company reporting $598,719 in sales for the 6 months ended October 31, 2021 due to the rapid covid tests
-
GPOX is currently raising $5 million for expansion and acquisitons
See GPOX Investor Deck here
______________________________
Good Afternoon Traders,
Our New Profile is GPO Plus Inc (OTCMKTS: GPOX)
GPOX is fully reporting OTCQB with just 29.3 million shares outstanding and sitting at 52 week lows at bottom of its range.
GPOX has a compelling chart setup: fully reporting OTCQB GPOX has a history of big moves skyrocketing to highs over $4 per share in July 2020. The stock also spent most of 2021 over $2 per share. Currently at $0.51 GPOX is trading right at the bottom of its range and very near all-time lows.
GPO Plus Inc (OTCMKTS: GPOX)is a Group Purchasing Organization or “GPO” for the Healthcare industry. Headquartered in Las Vegas, Nevada, GPO Plus, Inc. (OTCQB:GPOX) is a publicly traded global holding company of industry-specific Group Purchasing Organizations (GPO). The main holdings are HealthGPO, a Group Purchasing Organization for the Healthcare industry, cbdGPO, a Group Purchasing Organization for the CBD and Hemp industry, and GPOPRO.
GPOX revenues have been growing fast over the past few months with the Company reporting $598,719 in sales for the 6 months ended October 31, 2021compared to just $30,627 for the same period last year. According to CEO Brett H. Pojunis the rapid growth in revenues in due in large part to POC COVID test sales at AntiGenTests.com.
GPOX is raising $5,000,000 from Accredited Investors under its Securities and Exchange Commission (SEC) Reg D 506c offering. “GPOX plans to grow and is looking to attract new shareholders that want to grow with us,” said Company CEO, Brett H. Pojunis. The details of the Company’s Private Placement Memorandum (PPM) and investor presentation can be found at https://invest.gpoplus.com
GPOX main holdings are HealthGPO, a Group Purchasing Organization for the Healthcare industry also operating AntiGenTests.com, cbdGPO, a Group Purchasing Organization for the CBD and Hemp industry, and GPOPRO.
GPOPRO
a wholly owned subsidiary company of GPOX Services include:
- GPO PAY, low-cost reliable payment processing. GPOPlus+ works directly with institutions to provide low-cost and reliable payment processing services to our members.
- GPO SAFE-SHIP, a licensed, insured, and bonded shipping solution for our members. The primary focus is b2b, however, GPO SHIP-SAFE can safely deliver products Direct To Consumers as well.
- GPO INSURANCE, offering multiple types of insurance and coverage to our members.
- GPO SUPPLIES. GPO Supplies include custom packaging, labels, lab equipment and materials, apparel, merchandise, general printing, and promotional items to all members.
cbdGPO
cbdGPO is a membership Group Purchasing Organization (“GPO” or “buying group”) created to help CBD companies including wholesalers, manufacturers, distributors, and labs realize savings and efficiencies by aggregating purchasing volume and using that leverage to negotiate discounts with manufacturers, distributors, and other vendors. Following the Federal legalization of Hemp-CBD products in the United States, there is an overwhelming demand for high quality Hemp-CBD products for both consumers as well as businesses looking to break into this lucrative industry. cbdGPO exists to make our members successful. Our purpose is to ensure our members deliver safe, cost-effective CBD products to consumers.
HealthGPO
As a solution-specific Group Purchasing Organization for the Healthcare industry, GPOX business is represented by an increasing number of offerings across the broad spectrum of medical supplies, to include emerging medical and preventative products. HealthGPO is committed to becoming an alternative option for all the needs of today’s healthcare industry. As demand has increased for medical products, HealthGPO is responding by offering quality proven products at discounts (usually substantial discounts) without having to place substantial orders. HealthGPO is a division of GPO Plus, Inc. (OTC:GPOX)
AntiGenTests.com is a project of HealthGPO, and its mission is to provide everyone with access to affordable, accurate Covid testing through our secure, sustainable supply chain, distribution network, and the power of Group Purchasing.
GPOX’s AntiGenTests.com currently has 3 different covid rapid test kits on sale:
CareStart™ COVID-19 Antigen Test
The CareStart™ COVID-19 Antigen Home Test is a lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigens from SARS-CoV-2.Under FDA’s EUA, the CareStart™ COVID-19 Antigen Home Test is authorized for non-prescription home use with self-collected anterior nasal (nares) swab samples from individuals aged 14 years or older with symptoms of COVID-19 within the first 7 days of symptom onset. This test is also authorized for non-prescription home use with adult-collected nasal (nares) swab samples from individuals aged 2 years or older with symptoms of COVID-19 within the first 7 days of symptom onset.
This test is also authorized for non-prescription home use with self-collected anterior nasal (nares) swab samples from individuals aged 14 years or older, or adult-collected anterior nasal (nares) swab samples from individuals aged 2 years or older, with or without symptoms or other epidemiological reasons to suspect COVID-19 when tested twice over three days with at least 24 hours (and no more than 48 hours) between tests.
Flowflex™ COVID-19 Antigen Test
The FlowFlex™ COVID-19 Antigen Home Test is authorized for non-prescription home use with self-collected direct anterior nasal (nares) swab samples from individuals aged 14 years or older or adult collected direct anterior nasal swab samples from individuals aged two years or older. For use under an Emergency Use Authorization (EUA) only for the duration of the COVID-19 declaration justifying the emergency use of in vitro diagnostics (IVD), unless it is terminated or revoked by the FDA (after which the test may no longer be used)
RAPID DIAGNOSTIC TEST FOR THE DETECTION OF SARS-COV-2 ANTIGEN iHealth® Rapid Antigen Home Test – 2ct. Two (2) individual test per box. Rapid point-of-care (POC) test with results in minutes.
iHealth® COVID-19 Antigen Test
The iHealth® COVID-19 Antigen Rapid Test is a lateral flow assay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2. This test is authorized for non-prescription home use with self-collected anterior nasal (nares) swab samples from individuals aged 15 years or older with symptoms of COVID-19 within the first 7 days of symptom onset. This test is also authorized for non-prescription home use with adult-collected nasal swab samples from individuals aged 2 years or older with symptoms of COVID-19 within the first 7 days of symptom onset. This test is also authorized for non-prescription home use with self-collected anterior nasal (nares) swab samples from individuals aged 15 years or older, or adult collected anterior nasal swab samples from individuals aged 2 years or older, with or without symptoms or other epidemiological reasons to suspect COVID-19 when tested twice over three days with at least 24 hours (and no more than 48 hours) between tests.
RAPID DIAGNOSTIC TEST FOR THE DETECTION OF SARS-COV-2 ANTIGEN iHealth® Rapid Antigen Home Test – 2ct. Two (2) individual test per box. Rapid point-of-care (POC) test with results in minutes
Regarding the Rapid Point-of-Care COVID-19 Antigen Tests GPOX President Ron McCormick stated: “Over the last year we (HealthGPO) have worked tirelessly to maintain a consistent supply of POC COVID tests while preserving the best and most competitive pricing available. One of the best things we’ve been able to do is to help POC facilities from getting massive fines. Due to the COVID test supply shortages, one of GPOX main value propositions has been getting tests delivered the next day! As long as the order is paid for by 6:00 PM Eastern, we can usually get the tests delivered the next business day. Now our members don’t have to worry about the supply chain issues.”
Rapid Point-of-Care COVID-19 Antigen Tests detect the presence or absence of SARS-CoV-2 viral protein which is the virus that causes COVID-19. Rapid Point-of-Care (POC) tests provide results within minutes (depending on the test) and are used to diagnose current or detect past SARS-CoV-2 infections in various settings, such as Physician offices, Urgent care facilities, Pharmacies, School health clinics, long term care facilities, and nursing homes, and temporary locations, such as drive-through sites managed by local organizations.
All COVID-19 tests distributed through AntigenTests.com are authorized for use at the Point of Care (POC), i.e., inpatient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.AntigenTests.com is dedicated to Point-of-Care medical professionals.
During a recent interview, CEO Brett H. Pojunis discussed GPOX: (click here for interview)
- the GPOX business model of creating industry-specific GPOscompared to business models of traditional Group Purchasing Organizations and/or Buying Groups
- leadership’s focus on HealthGPO and further developing its business model the Company’s exiting stealth mode with a new sustainable and disruptive business model
- how GPOX achieved a significant milestone generating over $1 Million in revenue
- the expansion of its Leadership team to include a new Chief Financial Officer (CFO), Laurence Ruhe, and new President, Ron McCormick
- the Company’s $5 Million Equity Crowdfunding Offering is open for the public and viewable at invest.gpoplus.com
- why it’s a good time for investors to look at GPOPlus+, ticker: GPOX
__________
GPO PLUS INC. Brett H. Pojunis, CEO Laurence Ruhe, CFO Michael Fugler, Consultant Kevin G Malone, Consultant https://gpoplus.com/ https://healthgpo.com/ https://antigentests.com/
SECURITY DETAILS TICKER: OTCQB: GPOX OS: 29,332,509 MARKET CAP: $14,959,580
GPOX has a compelling chart setup: fully reporting OTCQB GPOX has a history of big moves skyrocketing to highs over $4 per share in July 2020. The stock also spent most of 2021 over $2 per share. Currently at $0.51 GPOX is trading right at the bottom of its range and very near all time lows.
GPOX RECENT NEWS